Form 6-K Cardiol Therapeutics For: May 25

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2026

 

Commission File Number: 001-40712

 

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

 

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

¨ Form 20-F   x Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

 

SUBMITTED HEREWITH

 

 

Exhibits

 

	99.1	Notice of Annual General Meeting of Shareholders
	99.2	Management Information Circular
	99.3	Form of Proxy
	99.4	Notice of Availability of Proxy Materials

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: May 25, 2026	By:	/s/ Christopher Waddick
		Name:	Christopher Waddick
		Title:	Chief Financial Officer

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

EXHIBIT 99.2

EXHIBIT 99.3

EXHIBIT 99.4

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
• Cox, Castle & Nicholson Advises on $4.95 Billion Financing of IPX Power’s Darden Solar and Storage Project
• Gorvulikent Reviews: Can Gorvulikent Trading Platform Deliver on Its Promises?